| (Values in U.S. Thousands) | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 |
| Sales | 0 | 0 | 0 | 0 | 650 |
| Sales Growth | unch | unch | unch | -100.00% | unch |
| Net Income | -81,310 | -57,880 | -35,930 | -53,960 | -24,420 |
| Net Income Growth | -40.48% | -61.09% | +33.41% | -120.97% | unch |
Cybin Inc
(CYBN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cybin Inc. is a biotechnology company. It is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin Inc. is based in Toronto, Canada.